Clorox Q4 net sales -6% to $1.9B; adjusted EPS +9% to $1.82; divests VMS business

CLOROX CO /DE/

2024-FY EPS reported $2.25 revenue$7,093,000,000

Q4 GAAP diluted EPS $1.73 (+22% YoY); adjusted EPS $1.82 (+9%) vs $1.67.
Gross margin 46.5% (+380 bps) on lower costs; organic sales -3%.
Announces sale of Better Health VMS business to Piping Rock Health Products; no deal value disclosed.
FY24 free cash flow $483M vs $930M; net cash from ops $695M.
FY25 outlook: expects return to volume growth consistent with long-term goals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.